We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.57%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$17.3B
AUM Growth
+$91.5M
(+0.53%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
1.94%
Top 10 Holdings %
Top 10 Hldgs %
59.81%
Holding
1,066
New
76
Increased
460
Reduced
487
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hess Midstream
HESM
|
+$99M |
| 2 |
Plains All American Pipeline
PAA
|
+$94.7M |
| 3 |
Enterprise Products Partners
EPD
|
+$41.7M |
| 4 |
Western Midstream Partners
WES
|
+$32.4M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$32.7M |
| 2 |
Energy Transfer Partners
ET
|
+$18.7M |
| 3 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$17M |
| 4 |
Cameco
CCJ
|
+$14.7M |
| 5 |
Cheniere Energy
CQP
|
+$13.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 68.28% |
| 2 | Technology | 4.29% |
| 3 | Financials | 3.4% |
| 4 | Consumer Discretionary | 2.95% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Regenxbio
RGNX
$623M
| $222K | ﹤0.01% |
+27,045
| New | +$226K |
|
|
TRML
1002
DELISTED
Tourmaline Bio
TRML
| $221K | ﹤0.01% |
13,846
-3,655
| -21% | -$59.2K |
|
|
ZBIO
1003
Zenas BioPharma
ZBIO
$1.92B
| $219K | ﹤0.01% |
22,553
-5,579
| -20% | -$54.3K |
|
|
MBX
1004
MBX Biosciences
MBX
$2.95B
| $206K | ﹤0.01% |
18,048
-7,986
| -31% | -$81.4K |
|
|
ITOS
1005
DELISTED
iTeos Therapeutics
ITOS
| $206K | ﹤0.01% |
20,653
-7,993
| -28% | -$64.4K |
|
1006
Rezolute
RZLT
$480M
| $206K | ﹤0.01% |
46,105
+3,019
| +7% | +$11.2K |
|
1007
Erasca
ERAS
$6.63B
| $194K | ﹤0.01% |
152,827
-57,456
| -27% | -$76.9K |
|
1008
Compass Therapeutics
CMPX
$373M
| $194K | ﹤0.01% |
+74,597
| New | +$154K |
|
1009
Arcturus Therapeutics
ARCT
$157M
| $190K | ﹤0.01% |
14,619
-5,330
| -27% | -$63K |
|
|
BCYC
1010
Bicycle Therapeutics
BCYC
$270M
| $179K | ﹤0.01% |
+25,757
| New | +$205K |
|
1011
Prothena Corp
PRTA
$458M
| $176K | ﹤0.01% |
29,028
-8,928
| -24% | -$67K |
|
|
TERN
1012
DELISTED
Terns Pharmaceuticals
TERN
| $176K | ﹤0.01% |
+47,156
| New | +$147K |
|
1013
Atea Pharmaceuticals
AVIR
$379M
| $166K | ﹤0.01% |
+46,165
| New | +$138K |
|
|
ATXS
1014
DELISTED
Astria Therapeutics
ATXS
| $163K | ﹤0.01% |
30,424
-13,020
| -30% | -$63.1K |
|
|
RC
1015
Ready Capital
RC
$265M
| $162K | ﹤0.01% |
37,002
-1,396
| -4% | -$6.2K |
|
1016
Olema Pharmaceuticals
OLMA
$1.02B
| $157K | ﹤0.01% |
36,910
-13,574
| -27% | -$60.5K |
|
1017
Gossamer Bio
GOSS
$66.5M
| $151K | ﹤0.01% |
+122,644
| New | +$134K |
|
1018
Vanda Pharmaceuticals
VNDA
$312M
| $150K | ﹤0.01% |
31,759
-10,234
| -24% | -$44.8K |
|
1019
Annexon
ANNX
$855M
| $142K | ﹤0.01% |
59,201
-23,425
| -28% | -$47K |
|
1020
Critical Metals Corp
CRML
$853M
| $142K | ﹤0.01% |
39,674
+2,875
| +8% | +$5.24K |
|
|
CMPS
1021
Compass Pathways
CMPS
$1.52B
| $141K | ﹤0.01% |
50,433
-15,798
| -24% | -$59.5K |
|
1022
Candel Therapeutics
CADL
$700M
| $137K | ﹤0.01% |
+27,045
| New | +$139K |
|
1023
SITE Centers
SITC
$230M
| $116K | ﹤0.01% |
10,243
-386
| -4% | -$4.63K |
|
|
YMAB
1024
DELISTED
Y-mAbs Therapeutics
YMAB
| $110K | ﹤0.01% |
24,429
-8,880
| -27% | -$39.9K |
|
1025
American Battery Technology Co
ABAT
$301M
| $65.8K | ﹤0.01% |
40,638
+10,610
| +35% | +$13.8K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, ALPS Advisors held 1,066 positions worth $17.3B, up 0.53% from $17.2B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
ALPS Advisors's Q2 2025 filing shows 76 new, 460 increased, 487 reduced and 41 closed positions. Its largest new stake was ALPS Dynamic US Dividend Advantage ETF: 231,612 shares worth $13.4M. The largest sale was Schwab Fundamental US Large Company Index ETF, an estimated $32.7M.
By sector, the portfolio is most concentrated in Energy at 68% of assets, down from 70% a quarter earlier, followed by Technology and Financials.
- ALPS Advisors's largest Q2 2025 buy was ALPS Dynamic US Dividend Advantage ETF: 231,612 shares worth $13.4M.
- ALPS Advisors added most to Hess Midstream in Q2 2025, an estimated $99M increase.
- ALPS Advisors's biggest Q2 2025 reduction was Energy Transfer Partners, cutting an estimated $18.7M.
- ALPS Advisors fully exited Schwab Fundamental US Large Company Index ETF in Q2 2025, selling an estimated $32.7M.
- ALPS Advisors's ten largest holdings make up 60% of its $17.3B portfolio in Q2 2025.
- ALPS Advisors opened 76 new positions and closed 41 in Q2 2025.
- ALPS Advisors's portfolio value rose 0.53% quarter-over-quarter to $17.3B.
Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.